Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (2675)	10/2/2001 8:08:19 PM
From: mopgcw	Respond to of 4974

It is the reincarnation of Celtrix and they do not appear on many radar screens. In addition to diabetes, also applications to PCOS and Osteoperosis. somatokine could also have application to burn victims if they ever get the $$ to push that one into trials. Also note they have a third candidate TGF-b2, that Genzyme has licensed to develop and is apparently in phase II for dermal repair per the genzyme website. i could not find any real info on this arrangement however. i have owned them since their celtrix days and recently bought another batch at $3. their timing on the cash raise was quite good, and as you noted, they have enough money to see it through. should be interesting. i have posted some of the relevant papers on the insm board. regards, george